Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Bepridil is a dihydropyridine that has anti-anginal and anti-arrhythmic actions by blocking calcium channels in heart and smooth muscle.1,2 It is recognized as a non-selective channel blocker, altering myocardial Ca2+, Na+, and K+ currents.3 For example, it blocks voltage-gated Ca2+ (Cav3.2) and K+ (hERG and KCNQ4) channels, sarcoplasmic ATP-sensitive K+ (KATP) channels, and Na+-activated (KNa) channels (IC50s = 7.1, 22, 9.4, 10, and 2.2 µM, respectively).4,5,6,2 It also activates mitochondrial ATP-sensitive KATP channels (ED50 = 27.5 µM).7
WARNING This product is not for human or veterinary use.
1. The mechanism of action of calcium antagonists relative to their clinical applications. Br. J. Clin. Pharmacol. 21(Suppl 2), 109S-121S (1986).
2. Molecular pharmacology of human Cav3.2 T-
3. Effect of bepridil in atrial fibrillation inducibility facilitated by vagal nerve stimulation. Prevention of vagal nerve activation-
4. Predicting hERG activities of compounds from their 3D structures: Development and evaluation of a global descriptors based QSAR model. Eur. J. Med. Chem. 46(2), 618-630 (2011).
5. KCNQ4 channels expressed in mammalian cells: Functional characteristics and pharmacology. Am. J. Physiol. Cell Physiol. 280(4), C859-C866 (2001).
6. Bepridil blunts the shortening of action potential duration caused by metabolic inhibition via blockade of ATP-
7. Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J. Pharmacol. Exp. Ther. 316(1), 182-188 (2006).